+21%

est. 2Y upside i

DevOps & InfraAI & MLSeries A

Train AI on distributed data

Rank

#2949

Sector

Developer Tools, Artificial Intelligence, Machine Learning

Est. Liquidity

~5Y

Data Quality

Data: Medium

Flower is a high-risk equity bet for a candidate joining at the $100M Series A valuation with $7.2M in revenue (13.9x ARR).

Last updated: May 5, 2026

Bull (10%)+200%

EU AI Act and HIPAA enforcement create regulatory mandates for privacy-preserving ML, driving rapid enterprise adoption; Flower raises Series B at $250M+ and is acquired by a cloud provider at $300-400M by 2028. Revenue scales to $20-25M on wins in pharma and financial services, delivering roughly 3x gross return on the $100M entry before dilution.

Base (55%)+50%

Flower grows 50-70% YoY reaching $12-15M revenue by mid-2028 and raises a Series B at $150-180M — a 1.5-1.8x paper gain from the $100M entry — but the company remains pre-liquidity. Employees see limited realized gain within the 2-year window as a Series C and eventual exit remain 3-4 years beyond that.

Bear (35%)-75%

Google, NVIDIA, and IBM continue offering competing federated learning frameworks at zero marginal cost, suppressing Flower's enterprise pricing and slowing growth below 30% YoY. Series B is delayed or priced at a flat-to-down round near $80-90M, and the $24.1M liquidation preference stack means common stockholders receive near-zero proceeds in any sub-$80M exit.

Est. time to liquidity~4.5 years

Preference Stack Risk

high

Funding Intensity

24%

Total funding of $24.1M against a $100M valuation yields a 24.1% preference ratio; in any exit at or below ~$30M, liquidation preferences fully absorb all proceeds and common stockholders receive nothing.

Dilution Risk

high

As a Series A company requiring an estimated 2-3 additional capital raises before a liquidity event, employees should model 30-50% cumulative dilution from future preferred issuances before any exit.

Secondary Liquidity

none

No secondary market activity is evident for an 81-person Series A company; equity should be treated as fully illiquid until a formal liquidity event such as an acquisition or IPO.

Questions to Ask at the Interview

Strategic questions based on Flower's data — designed to show you've done your homework.

  • 1

    “What is Flower's current ARR growth rate year-over-year, and what was revenue at the time of the February 2024 Series A close — can you walk me through the revenue bridge?”

  • 2

    “What is the average ACV and sales cycle length for an enterprise contract, and how does Flower convert open-source users to paid customers at scale against Google and NVIDIA's free alternatives?”

  • 3

    “What is the current fully diluted share count, the size of the employee option pool reserved for future hires, and at what strike price would my grant be issued — and is there a secondary tender program in place?”

Community

Valuation Sentiment

Our model estimates +21% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.